D C Seldin
Overview
Explore the profile of D C Seldin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1395
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee S, Meehan R, Seldin D, Sloan J, Quillen K, Shelton A, et al.
Bone Marrow Transplant
. 2016 May;
51(10):1318-1322.
PMID: 27183092
High-dose melphalan with stem cell transplantation (HDM/SCT) extends survival and induces hematologic and clinical responses in patients with light chain (AL) amyloidosis. Eighty percent of melphalan is bound to plasma...
2.
Renteria A, Sanchorawala V, Niehaus E, Sun F, Semigran M, Seldin D
Bone Marrow Transplant
. 2015 Mar;
50(6):868-9.
PMID: 25751645
No abstract available.
3.
Freeman B, Brauneis D, Seldin D, Quillen K, Sloan J, Renteria A, et al.
Bone Marrow Transplant
. 2014 Jun;
49(10):1345-6.
PMID: 24955784
No abstract available.
4.
Girnius S, Seldin D, Meier-Ewert H, Sloan J, Quillen K, Ruberg F, et al.
Bone Marrow Transplant
. 2013 Dec;
49(3):434-9.
PMID: 24317129
In Ig light chain (AL) amyloidosis, cardiac involvement is associated with worse prognosis and increased treatment-related complications. In this retrospective cohort study, we assessed survival, hematologic and cardiac responses to...
5.
Sanchorawala V, Hoering A, Seldin D, Finn K, Fennessey S, Sexton R, et al.
Bone Marrow Transplant
. 2013 Jul;
48(12):1537-42.
PMID: 23852321
We designed a trial using two sequential cycles of modified high-dose melphalan at 100 mg/m(2) and autologous SCT (mHDM/SCT) in AL amyloidosis (light-chain amyloidosis, AL), AL with myeloma (ALM) and...
6.
Taimur S, Nader C, Lloyd-Travaglini C, Seldin D, Sanchorawala V
Transpl Infect Dis
. 2013 Jan;
15(2):187-94.
PMID: 23279695
Background: Immunoglobulin light chain (AL) amyloidosis can be treated with high-dose melphalan and autologous stem cell transplantation (HDM/SCT). Risk factors for infections may include hyposplenism, hypogammaglobulinemia, treatment-related neutropenia, melphalan-induced mucositis,...
7.
Connors L, Doros G, Sam F, Badiee A, Seldin D, Skinner M
Amyloid
. 2011 Aug;
18 Suppl 1:157-9.
PMID: 21838471
No abstract available.
8.
Meier-Ewert H, Sanchorawala V, Berk J, Finn K, Skinner M, Seldin D, et al.
Amyloid
. 2011 Aug;
18 Suppl 1:130-1.
PMID: 21838460
No abstract available.
9.
Seldin D, Andrea N, Berenbaum I, Berk J, Connors L, Dember L, et al.
Amyloid
. 2011 Aug;
18 Suppl 1:127-9.
PMID: 21838459
No abstract available.
10.
Ward J, SooHoo P, Toraldo G, Jasuja R, Connors L, OHara C, et al.
Amyloid
. 2011 Aug;
18 Suppl 1:40-1.
PMID: 21838426
No abstract available.